Synthesis and In Vitro Cytotoxic Evaluation of Novel Indole-Based Hydrazone Derivatives Against Breast Cancer Cell Lines
DOI:
https://doi.org/10.5281/zenodo.22644079Keywords:
indole hydrazone, hydrazide-hydrazone derivatives, breast cancer cytotoxicity, MCF-7 and MDA-MB-231 cell lines, structure-activity relationshipAbstract
Background: Breast cancer remains the most commonly diagnosed malignancy in women worldwide, and the indole nucleus,
functionalized as a hydrazone or hydrazide-hydrazone, has emerged as a synthetically accessible and biologically productive
scaffold for anticancer drug discovery. Objective: This narrative review synthesizes published literature on the synthesis,
structure-activity relationships, and in vitro cytotoxic evaluation of indole-based hydrazone and hydrazide-hydrazone derivatives
against breast cancer cell lines. Methods: We reviewed synthetic, structure-activity, and mechanistic studies of indole-hydrazone
chemotypes screened against MCF-7 and MDA-MB-231 breast cancer cells, focusing on condensation-based synthetic routes,
substituent-driven potency trends, reported IC50 and selectivity data, and proposed molecular targets. Findings: Indole-hydrazones
are consistently accessed by acid-catalyzed condensation of an indole carbaldehyde or carbohydrazide with acylhydrazides or
sulfonohydrazides, often after N1-tosylation or N1-benzylation, and electron-withdrawing, halogenated, and appropriately
positioned aryl substituents recur as determinants of potency. Reported activities span low-nanomolar to mid-micromolar IC50
values against MCF-7 and MDA-MB-231 cells, frequently accompanied by wide selectivity margins over normal breast epithelial or
embryonic kidney cells, with kinase inhibition, histone deacetylase-2 inhibition, and computationally predicted target engagement
each proposed as underlying mechanisms in different series. Conclusions: Indole-based hydrazone and hydrazide-hydrazone
derivatives constitute a promising and chemically tractable class of breast cancer cytotoxic agents, though compound-specific
mechanistic validation remains needed as the class advances toward more detailed pharmacological characterization.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3):229-263, DOI:10.3322/caac.21834.
Wan Y, Li Y, Yan C, Yan M, Tang Z (2019) Indole: A privileged scaffold for the design of anti-cancer agents. European Journal of Medicinal Chemistry, 183:111691, DOI:10.1016/j.ejmech.2019.111691.
Hassan SM, Farid A, Panda SS, Bekheit MS, Dinkins H, Fayad W, Girgis AS (2024) Indole Compounds in Oncology: Therapeutic Potential and Mechanistic Insights. Pharmaceuticals, 17(7):922, DOI:10.3390/ph17070922.
Debnath B, Nandi B, Paul S, Manna S, Maity A, Bandyopadhyay K, Panda S, Khan SA, Nath R, Akhtar MJ (2025) Novel indole-based synthetic molecules in cancer treatment: Synthetic strategies and structure-activity relationship. Medicine in Drug Discovery, 27:100208, DOI:10.1016/j.medidd.2025.100208.
Murugappan S, Dastari S, Jungare K, Barve NM, Shankaraiah N (2024) Hydrazide-hydrazone/hydrazone as enabling linkers in anti-cancer drug discovery: A comprehensive review. Journal of Molecular Structure, 1307:138012, DOI:10.1016/j.molstruc.2024.138012.
Hassan EM, Soliman SM, Moneer EA, Hagar M, Barakat A, Haukka M, Rasheed H (2023) Synthesis, X-ray Structure, Hirshfeld, DFT Conformational, Cytotoxic, and Anti-Toxoplasma Studies of New Indole-Hydrazone Derivatives. International Journal of Molecular Sciences, 24(17):13251, DOI:10.3390/ijms241713251.
Mahdi ZH, Alsalim TA, Abdulhussein HA, Majed AA, Abbas S (2024) Synthesis, molecular docking, and anti-breast cancer study of 1-H-indol-3-Carbohydrazide and their derivatives. Results in Chemistry, 11:101762, DOI:10.1016/j.rechem.2024.101762.
Ghaffar U, Khan F, Hussain J, Mali SN, Khan A, Chaudhari SY, Jawarkar RD, Alanazi AK, Ul Islam W, Ismail MA, Al-Harrasi A, Shafiq Z (2025) In-vitro and in-silico study to assess anti breast cancer potential of N-tosyl-indole based hydrazones. Scientific Reports, 15:35733, DOI:10.1038/s41598-025-21326-6.
Farooq U, Khan F, Mali SN, Ghaffar U, Hussain J, Khan A, Chaudhary SY, AL-Shwaimah HA, Elgorbany AM, Jawarkar RD, Ul Islam W, Al-Harrasi A, Shafiq Z (2025) In vitro and in silico analysis of synthesized N-benzyl indole-derived hydrazones as potential anti-triple negative breast cancer agents. RSC Advances, 15(17):13284-13299, DOI:10.1039/D5RA02194D.
Munira I, Batool Z, Khan F, Hussain J, Khan A, Mali SN, Radhakrishnan VV, Mathew B, Almutairi TM, Al-Harrasi A, Akram MS, Shafiq Z (2025) Design, synthesis, in vitro, and in silico studies of novel isatin-hybrid hydrazones as potential triple-negative breast cancer agents. RSC Advances, 15(2):948-965, DOI:10.1039/D4RA07650H.
Angelova VT, Tatarova T, Mihaylova R, Vassilev N, Petrov B, Zhivkova Z, Doytchinova I (2023) Novel Arylsulfonylhydrazones as Breast Anticancer Agents Discovered by Quantitative Structure-Activity Relationships. Molecules, 28(5):2058, DOI:10.3390/molecules28052058.
Angelova VT, Mihaylova R, Zhivkova Z, Vassilev N, Shivachev B, Doytchinova I (2025) Novel Indole-Based Sulfonylhydrazones as Potential Anti-Breast Cancer Agents: Synthesis, In Vitro Evaluation, ADME, and QSAR Studies. Pharmaceuticals, 18(8):1231, DOI:10.3390/ph18081231.
Salama EE, Youssef MF, Aboelmagd A, Boraei ATA, Nafie MS, Haukka M, Barakat A, Sarhan AAM (2023) Discovery of Potent Indolyl-Hydrazones as Kinase Inhibitors for Breast Cancer: Synthesis, X-ray Single-Crystal Analysis, and In Vitro and In Vivo Anti-Cancer Activity Evaluation. Pharmaceuticals, 16(12):1724, DOI:10.3390/ph16121724.
Sreenivasulu R, Sujitha P, Jadav SS, Ahsan MJ, Kumar CG, Raju RR (2017) Synthesis, antitumor evaluation, and molecular docking studies of indole-indazolyl hydrazide-hydrazone derivatives. Monatshefte für Chemie - Chemical Monthly, 148(2):305-314, DOI:10.1007/s00706-016-1750-6.
Feizi-Dehnayebi M, Mohammadi Ziarani G, Reiisi S, Farsadrooh M, Panahande Z, Mansouri-Torshizi H, Akkoc S (2025) Biological evaluations and biomolecular interactions along with computational insights of arylidene isatin hydrazones synthesized using nanocatalyst. Scientific Reports, 15:42705, DOI:10.1038/s41598-025-26721-7.
Naghi-Ganji N, Saghaei L, Tavakoli F, Azimian V, Mirian M, Sirous H, Rostami M (2022) Design, synthesis, and cytotoxicity evaluation of novel indole-acylhydrazone derivatives of 4-pyridinone as potential histone deacetylase-2 inhibitors. Research in Pharmaceutical Sciences, 17(5):572-584, DOI:10.4103/1735-5362.355214.
